Determinants of resistance to VEGF-TKI and immune checkpoint inhibitors in metastatic renal cell carcinoma

Vascular endothelial growth factor tyrosine kinase inhibitors (VEGF-TKIs) have been the mainstay of treatment for patients with advanced renal cell carcinoma (RCC). Despite its early promising results in decreasing or delaying the progression of RCC in patients, VEGF-TKIs have provided modest benefi...

Descripción completa

Detalles Bibliográficos
Autores principales: Sharma, Revati, Kadife, Elif, Myers, Mark, Kannourakis, George, Prithviraj, Prashanth, Ahmed, Nuzhat
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2021
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8183071/
https://www.ncbi.nlm.nih.gov/pubmed/34099013
http://dx.doi.org/10.1186/s13046-021-01961-3

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8183071/
https://www.ncbi.nlm.nih.gov/pubmed/34099013
http://dx.doi.org/10.1186/s13046-021-01961-3

Ejemplares similares